| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 93 | 2020 | 1032 | 11.030 |
Why?
|
| Liver Cirrhosis | 105 | 2022 | 1961 | 10.540 |
Why?
|
| Antiviral Agents | 79 | 2022 | 3053 | 6.990 |
Why?
|
| Ribavirin | 48 | 2018 | 395 | 5.730 |
Why?
|
| Elasticity Imaging Techniques | 25 | 2024 | 397 | 5.190 |
Why?
|
| Hepacivirus | 55 | 2021 | 1343 | 4.520 |
Why?
|
| Fluorenes | 16 | 2017 | 160 | 4.200 |
Why?
|
| Uridine Monophosphate | 15 | 2017 | 67 | 3.420 |
Why?
|
| Hepatitis C | 32 | 2021 | 1596 | 3.370 |
Why?
|
| Benzimidazoles | 16 | 2017 | 862 | 3.150 |
Why?
|
| Thrombocytopenia | 14 | 2021 | 1172 | 2.450 |
Why?
|
| Liver Diseases | 13 | 2024 | 1304 | 2.250 |
Why?
|
| Hepatitis B, Chronic | 10 | 2022 | 413 | 2.210 |
Why?
|
| Interferon-alpha | 31 | 2015 | 909 | 1.990 |
Why?
|
| Liver | 52 | 2024 | 7559 | 1.850 |
Why?
|
| Alanine Transaminase | 17 | 2017 | 608 | 1.610 |
Why?
|
| Benzoates | 5 | 2014 | 213 | 1.600 |
Why?
|
| Hydrazines | 5 | 2014 | 223 | 1.580 |
Why?
|
| Fatty Liver | 14 | 2024 | 810 | 1.490 |
Why?
|
| Polyethylene Glycols | 27 | 2015 | 1189 | 1.390 |
Why?
|
| Cinnamates | 2 | 2021 | 59 | 1.360 |
Why?
|
| Receptors, Thrombopoietin | 6 | 2021 | 158 | 1.340 |
Why?
|
| Genotype | 32 | 2021 | 13026 | 1.310 |
Why?
|
| Hematologic Agents | 3 | 2014 | 39 | 1.280 |
Why?
|
| Carcinoma, Hepatocellular | 14 | 2021 | 2325 | 1.230 |
Why?
|
| Interleukins | 9 | 2012 | 789 | 1.180 |
Why?
|
| Interferons | 14 | 2017 | 714 | 1.150 |
Why?
|
| Postoperative Hemorrhage | 2 | 2021 | 418 | 1.040 |
Why?
|
| Liver Neoplasms | 15 | 2021 | 4349 | 1.020 |
Why?
|
| Blood Loss, Surgical | 2 | 2021 | 642 | 1.010 |
Why?
|
| Platelet Transfusion | 3 | 2021 | 301 | 0.970 |
Why?
|
| Liver Transplantation | 10 | 2017 | 2418 | 0.940 |
Why?
|
| Mucins | 15 | 2006 | 568 | 0.940 |
Why?
|
| Drug Therapy, Combination | 35 | 2018 | 6306 | 0.930 |
Why?
|
| Biopsy | 35 | 2021 | 6766 | 0.900 |
Why?
|
| Viral Load | 18 | 2017 | 3385 | 0.900 |
Why?
|
| Pyrazoles | 5 | 2014 | 2031 | 0.850 |
Why?
|
| Hypertension, Portal | 6 | 2021 | 229 | 0.840 |
Why?
|
| Thiazoles | 2 | 2021 | 1528 | 0.810 |
Why?
|
| Gallbladder | 14 | 2006 | 308 | 0.780 |
Why?
|
| Aspartate Aminotransferases | 11 | 2015 | 416 | 0.780 |
Why?
|
| RNA, Viral | 19 | 2018 | 2866 | 0.770 |
Why?
|
| Cholesterol | 18 | 2021 | 2902 | 0.750 |
Why?
|
| Hyaluronic Acid | 9 | 2013 | 483 | 0.720 |
Why?
|
| Proline | 4 | 2015 | 452 | 0.700 |
Why?
|
| Hepatitis B | 3 | 2022 | 709 | 0.690 |
Why?
|
| Esophageal and Gastric Varices | 3 | 2010 | 215 | 0.670 |
Why?
|
| Portal Pressure | 3 | 2021 | 62 | 0.640 |
Why?
|
| Gastric Mucins | 5 | 2009 | 19 | 0.640 |
Why?
|
| Recombinant Proteins | 33 | 2015 | 6491 | 0.640 |
Why?
|
| Drug Interactions | 2 | 2021 | 1416 | 0.630 |
Why?
|
| Cholelithiasis | 8 | 2006 | 408 | 0.620 |
Why?
|
| Middle Aged | 127 | 2024 | 223016 | 0.600 |
Why?
|
| Humans | 237 | 2024 | 765926 | 0.590 |
Why?
|
| Bile | 10 | 2005 | 300 | 0.580 |
Why?
|
| Imidazoles | 3 | 2018 | 1164 | 0.580 |
Why?
|
| Hepatic Veins | 2 | 2019 | 112 | 0.580 |
Why?
|
| Benzofurans | 1 | 2018 | 139 | 0.570 |
Why?
|
| Male | 151 | 2024 | 363815 | 0.550 |
Why?
|
| Vibration | 3 | 2015 | 334 | 0.540 |
Why?
|
| Hematinics | 5 | 2013 | 282 | 0.530 |
Why?
|
| Hepatitis B e Antigens | 6 | 2022 | 135 | 0.520 |
Why?
|
| Female | 150 | 2024 | 396141 | 0.520 |
Why?
|
| Oligopeptides | 4 | 2015 | 1193 | 0.520 |
Why?
|
| Drug Therapy | 1 | 2019 | 504 | 0.520 |
Why?
|
| Quinoxalines | 1 | 2018 | 296 | 0.510 |
Why?
|
| Adult | 107 | 2024 | 223088 | 0.500 |
Why?
|
| Silymarin | 6 | 2012 | 43 | 0.490 |
Why?
|
| End Stage Liver Disease | 4 | 2021 | 369 | 0.490 |
Why?
|
| Histocytochemistry | 3 | 2017 | 695 | 0.480 |
Why?
|
| Keratin-18 | 3 | 2016 | 37 | 0.480 |
Why?
|
| Disease Progression | 26 | 2022 | 13614 | 0.470 |
Why?
|
| Erythropoietin | 5 | 2013 | 716 | 0.470 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2014 | 788 | 0.470 |
Why?
|
| Cost-Benefit Analysis | 7 | 2017 | 5531 | 0.470 |
Why?
|
| Hepatitis, Viral, Human | 3 | 2015 | 141 | 0.460 |
Why?
|
| Liver Cirrhosis, Experimental | 2 | 2008 | 30 | 0.460 |
Why?
|
| Drug Administration Schedule | 9 | 2019 | 4851 | 0.460 |
Why?
|
| Chronic Disease | 13 | 2024 | 9351 | 0.460 |
Why?
|
| Protease Inhibitors | 2 | 2015 | 747 | 0.450 |
Why?
|
| Hepatic Encephalopathy | 2 | 2018 | 143 | 0.450 |
Why?
|
| Severity of Illness Index | 24 | 2021 | 15878 | 0.450 |
Why?
|
| Nucleosides | 1 | 2014 | 130 | 0.440 |
Why?
|
| Treatment Outcome | 43 | 2022 | 65194 | 0.440 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2019 | 746 | 0.440 |
Why?
|
| Perioperative Care | 1 | 2021 | 1042 | 0.420 |
Why?
|
| Predictive Value of Tests | 17 | 2016 | 15401 | 0.410 |
Why?
|
| Hepatitis, Chronic | 2 | 2016 | 53 | 0.410 |
Why?
|
| Cystadenocarcinoma | 1 | 2012 | 54 | 0.400 |
Why?
|
| Platelet Count | 9 | 2014 | 784 | 0.400 |
Why?
|
| Nucleotides | 1 | 2014 | 453 | 0.380 |
Why?
|
| Point-of-Care Systems | 2 | 2024 | 1218 | 0.370 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 551 | 0.370 |
Why?
|
| Liver Circulation | 3 | 2008 | 163 | 0.370 |
Why?
|
| Biopsy, Needle | 6 | 2012 | 1613 | 0.360 |
Why?
|
| Clinical Enzyme Tests | 1 | 2010 | 114 | 0.350 |
Why?
|
| Aged | 59 | 2021 | 171163 | 0.350 |
Why?
|
| Gallstones | 4 | 2010 | 285 | 0.350 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 3 | 2009 | 150 | 0.330 |
Why?
|
| Fibrosis | 9 | 2024 | 2073 | 0.330 |
Why?
|
| Benzazepines | 1 | 2011 | 308 | 0.330 |
Why?
|
| Liver Function Tests | 7 | 2011 | 527 | 0.320 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2010 | 95 | 0.320 |
Why?
|
| ROC Curve | 12 | 2021 | 3612 | 0.310 |
Why?
|
| Hyponatremia | 1 | 2011 | 278 | 0.310 |
Why?
|
| Basal Ganglia | 1 | 2011 | 549 | 0.310 |
Why?
|
| Carbamates | 3 | 2016 | 191 | 0.310 |
Why?
|
| Intracranial Hemorrhages | 1 | 2014 | 809 | 0.310 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2015 | 75 | 0.300 |
Why?
|
| Methylene Blue | 2 | 2007 | 157 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2019 | 10727 | 0.300 |
Why?
|
| Isoindoles | 1 | 2008 | 35 | 0.300 |
Why?
|
| Viral Nonstructural Proteins | 6 | 2016 | 227 | 0.300 |
Why?
|
| Prognosis | 18 | 2021 | 29890 | 0.300 |
Why?
|
| Anthropometry | 1 | 2012 | 1339 | 0.290 |
Why?
|
| Adenosine Deaminase | 2 | 2021 | 253 | 0.290 |
Why?
|
| Gastroenterology | 1 | 2014 | 593 | 0.280 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 428 | 0.280 |
Why?
|
| Anemia | 8 | 2013 | 1514 | 0.280 |
Why?
|
| Hemangioma | 1 | 2012 | 724 | 0.280 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2007 | 45 | 0.270 |
Why?
|
| Substance P | 1 | 2008 | 331 | 0.270 |
Why?
|
| Gastric Mucosa | 2 | 2009 | 602 | 0.270 |
Why?
|
| Sensitivity and Specificity | 15 | 2016 | 14643 | 0.260 |
Why?
|
| DNA, Viral | 4 | 2022 | 2196 | 0.260 |
Why?
|
| Administration, Oral | 7 | 2019 | 4016 | 0.260 |
Why?
|
| Health Care Costs | 3 | 2015 | 3241 | 0.260 |
Why?
|
| Confidence Intervals | 3 | 2019 | 2915 | 0.260 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2010 | 317 | 0.260 |
Why?
|
| Double-Blind Method | 19 | 2019 | 12417 | 0.250 |
Why?
|
| Crystallization | 10 | 2010 | 518 | 0.250 |
Why?
|
| Schistosomiasis | 1 | 2006 | 65 | 0.250 |
Why?
|
| Nitric Oxide Synthase | 2 | 2007 | 911 | 0.250 |
Why?
|
| Retrospective Studies | 20 | 2022 | 81537 | 0.240 |
Why?
|
| Drug Design | 1 | 2010 | 1039 | 0.240 |
Why?
|
| United States | 23 | 2024 | 72909 | 0.240 |
Why?
|
| Frontal Lobe | 1 | 2011 | 1408 | 0.240 |
Why?
|
| Glycoproteins | 6 | 2009 | 2196 | 0.240 |
Why?
|
| Collagen Type III | 1 | 2005 | 92 | 0.240 |
Why?
|
| Endosonography | 1 | 2009 | 626 | 0.240 |
Why?
|
| Hepatitis B virus | 2 | 2022 | 532 | 0.240 |
Why?
|
| Biochemistry | 1 | 2005 | 115 | 0.240 |
Why?
|
| Drug Resistance, Viral | 5 | 2016 | 867 | 0.230 |
Why?
|
| Cohort Studies | 16 | 2024 | 41680 | 0.230 |
Why?
|
| Guanine | 2 | 2017 | 281 | 0.230 |
Why?
|
| Prospective Studies | 24 | 2024 | 54807 | 0.230 |
Why?
|
| Blood Flow Velocity | 1 | 2008 | 1377 | 0.220 |
Why?
|
| Sarcina | 1 | 2023 | 10 | 0.220 |
Why?
|
| Serum | 3 | 2017 | 205 | 0.220 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 2022 | 293 | 0.220 |
Why?
|
| Adenoma | 2 | 2012 | 2155 | 0.220 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2019 | 179 | 0.220 |
Why?
|
| Young Adult | 20 | 2021 | 59857 | 0.210 |
Why?
|
| Microspheres | 2 | 2004 | 773 | 0.210 |
Why?
|
| Drug Combinations | 4 | 2018 | 2075 | 0.210 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 1127 | 0.210 |
Why?
|
| Stomach | 2 | 2023 | 702 | 0.210 |
Why?
|
| Aged, 80 and over | 17 | 2023 | 59496 | 0.210 |
Why?
|
| Health Services Research | 1 | 2010 | 1811 | 0.200 |
Why?
|
| Proteomics | 2 | 2024 | 3906 | 0.200 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 1657 | 0.200 |
Why?
|
| Sterols | 2 | 2004 | 63 | 0.200 |
Why?
|
| Benzamides | 2 | 2018 | 1376 | 0.200 |
Why?
|
| HIV Infections | 8 | 2014 | 17531 | 0.200 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 723 | 0.190 |
Why?
|
| Mass Screening | 2 | 2013 | 5449 | 0.190 |
Why?
|
| Interferon Type I | 1 | 2005 | 567 | 0.190 |
Why?
|
| Chemokine CXCL10 | 2 | 2014 | 310 | 0.190 |
Why?
|
| Kupffer Cells | 1 | 2021 | 144 | 0.180 |
Why?
|
| Bile Ducts | 2 | 2011 | 288 | 0.180 |
Why?
|
| Mitochondria, Liver | 1 | 2021 | 190 | 0.180 |
Why?
|
| Bile Duct Diseases | 1 | 2001 | 98 | 0.180 |
Why?
|
| Registries | 2 | 2016 | 8346 | 0.180 |
Why?
|
| Autocrine Communication | 1 | 2021 | 167 | 0.180 |
Why?
|
| Hepatic Stellate Cells | 2 | 2012 | 117 | 0.180 |
Why?
|
| Weight Loss | 1 | 2012 | 2710 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2021 | 10380 | 0.180 |
Why?
|
| Acetyltransferases | 1 | 2021 | 230 | 0.180 |
Why?
|
| Collagen | 5 | 2022 | 2616 | 0.180 |
Why?
|
| Ascites | 3 | 2018 | 336 | 0.170 |
Why?
|
| Quantitative Trait Loci | 2 | 2010 | 2136 | 0.170 |
Why?
|
| Cattle | 10 | 2004 | 3801 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2012 | 3466 | 0.170 |
Why?
|
| Quality Indicators, Health Care | 1 | 2010 | 1804 | 0.170 |
Why?
|
| Risk Assessment | 9 | 2024 | 24275 | 0.170 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2021 | 109 | 0.170 |
Why?
|
| Paracrine Communication | 1 | 2021 | 277 | 0.170 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2021 | 128 | 0.170 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 2170 | 0.170 |
Why?
|
| Cell-Derived Microparticles | 2 | 2012 | 160 | 0.170 |
Why?
|
| Tooth Extraction | 1 | 2021 | 225 | 0.160 |
Why?
|
| Lectins | 4 | 2013 | 487 | 0.160 |
Why?
|
| Adipokines | 4 | 2013 | 308 | 0.160 |
Why?
|
| Focal Nodular Hyperplasia | 2 | 2012 | 29 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 878 | 0.150 |
Why?
|
| Desmosine | 1 | 1997 | 19 | 0.150 |
Why?
|
| Endoscopy, Digestive System | 1 | 2021 | 358 | 0.150 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2017 | 20 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2018 | 36547 | 0.150 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2018 | 149 | 0.150 |
Why?
|
| Recurrence | 4 | 2014 | 8492 | 0.150 |
Why?
|
| Adenine | 2 | 2014 | 994 | 0.140 |
Why?
|
| Aging, Premature | 1 | 2018 | 44 | 0.140 |
Why?
|
| Neutropenia | 3 | 2011 | 894 | 0.140 |
Why?
|
| Cell Transplantation | 1 | 1999 | 473 | 0.140 |
Why?
|
| Cognition Disorders | 1 | 2011 | 3965 | 0.140 |
Why?
|
| Hepatitis B Virus, Woodchuck | 1 | 2017 | 6 | 0.140 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2016 | 157 | 0.140 |
Why?
|
| Procollagen | 3 | 2006 | 189 | 0.140 |
Why?
|
| Marmota | 1 | 2017 | 13 | 0.140 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 2004 | 0.140 |
Why?
|
| Radiography | 3 | 2019 | 6941 | 0.140 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2015 | 238 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 7423 | 0.140 |
Why?
|
| Crohn Disease | 3 | 1999 | 2281 | 0.140 |
Why?
|
| Anesthesia | 1 | 2008 | 1593 | 0.140 |
Why?
|
| Time Factors | 15 | 2018 | 40097 | 0.130 |
Why?
|
| Solutions | 3 | 2005 | 405 | 0.130 |
Why?
|
| Receptors, Concanavalin A | 2 | 1993 | 11 | 0.130 |
Why?
|
| Pyridines | 2 | 2018 | 2885 | 0.130 |
Why?
|
| Age Factors | 6 | 2016 | 18382 | 0.130 |
Why?
|
| Epoetin Alfa | 3 | 2004 | 78 | 0.130 |
Why?
|
| Viscosity | 4 | 2009 | 334 | 0.130 |
Why?
|
| Sigmoidoscopy | 1 | 1996 | 150 | 0.130 |
Why?
|
| Polymorphism, Genetic | 4 | 2012 | 4249 | 0.130 |
Why?
|
| Forecasting | 2 | 2019 | 2936 | 0.130 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 3716 | 0.120 |
Why?
|
| Concanavalin A | 2 | 1996 | 189 | 0.120 |
Why?
|
| Lipoproteins, VLDL | 1 | 2016 | 198 | 0.120 |
Why?
|
| Ammonia | 1 | 2016 | 244 | 0.120 |
Why?
|
| Cholesterol, Dietary | 2 | 2005 | 224 | 0.120 |
Why?
|
| Calcium Phosphates | 1 | 1995 | 171 | 0.120 |
Why?
|
| Carbon Tetrachloride | 2 | 2008 | 72 | 0.120 |
Why?
|
| Adolescent | 16 | 2021 | 88811 | 0.120 |
Why?
|
| RNA | 3 | 2022 | 2716 | 0.120 |
Why?
|
| Boston | 5 | 2014 | 9334 | 0.110 |
Why?
|
| Patient Care Management | 2 | 2007 | 301 | 0.110 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2013 | 174 | 0.110 |
Why?
|
| Aspirin | 2 | 2016 | 3135 | 0.110 |
Why?
|
| Animals | 33 | 2017 | 168735 | 0.110 |
Why?
|
| alpha-Fetoproteins | 3 | 2011 | 227 | 0.110 |
Why?
|
| Diagnostic Imaging | 2 | 2008 | 3530 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2018 | 2688 | 0.110 |
Why?
|
| Reproducibility of Results | 9 | 2019 | 20133 | 0.110 |
Why?
|
| New Zealand | 1 | 2014 | 359 | 0.110 |
Why?
|
| Ultrasonography, Doppler | 2 | 2007 | 462 | 0.110 |
Why?
|
| Liposomes | 1 | 1997 | 786 | 0.110 |
Why?
|
| Amino Acids | 2 | 1997 | 1709 | 0.110 |
Why?
|
| Aminopeptidases | 1 | 1994 | 113 | 0.110 |
Why?
|
| Waiting Lists | 2 | 2017 | 779 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 434 | 0.110 |
Why?
|
| Alprostadil | 1 | 1993 | 86 | 0.110 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2017 | 1740 | 0.110 |
Why?
|
| Follow-Up Studies | 12 | 2018 | 39228 | 0.110 |
Why?
|
| Pyrophosphatases | 2 | 2011 | 143 | 0.110 |
Why?
|
| Bilirubin | 3 | 2009 | 439 | 0.110 |
Why?
|
| Monocytes | 2 | 2021 | 2591 | 0.110 |
Why?
|
| Hydrogen-Ion Concentration | 5 | 2009 | 2476 | 0.100 |
Why?
|
| Cryptosporidiosis | 1 | 1993 | 52 | 0.100 |
Why?
|
| Models, Economic | 1 | 2017 | 716 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 3 | 2012 | 1996 | 0.100 |
Why?
|
| Lamivudine | 1 | 2014 | 368 | 0.100 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2012 | 7 | 0.100 |
Why?
|
| Liver Abscess, Amebic | 1 | 2012 | 19 | 0.100 |
Why?
|
| Swine | 7 | 2009 | 5986 | 0.100 |
Why?
|
| alpha-Macroglobulins | 2 | 2009 | 60 | 0.100 |
Why?
|
| Echinococcosis | 1 | 2012 | 32 | 0.100 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 418 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2012 | 16039 | 0.100 |
Why?
|
| Cholangitis | 1 | 1993 | 110 | 0.100 |
Why?
|
| Muscle Contraction | 1 | 1997 | 1207 | 0.100 |
Why?
|
| Quality of Life | 6 | 2015 | 13463 | 0.100 |
Why?
|
| Nucleotidyltransferases | 1 | 2014 | 242 | 0.100 |
Why?
|
| Interferon-gamma | 4 | 2012 | 3158 | 0.100 |
Why?
|
| Professional Practice | 1 | 2014 | 314 | 0.100 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2011 | 55 | 0.100 |
Why?
|
| Reference Values | 1 | 2019 | 4909 | 0.100 |
Why?
|
| Europe | 2 | 2018 | 3430 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2021 | 8924 | 0.090 |
Why?
|
| Prevalence | 6 | 2021 | 15828 | 0.090 |
Why?
|
| Scattering, Radiation | 3 | 1999 | 482 | 0.090 |
Why?
|
| Cholestasis | 1 | 2014 | 385 | 0.090 |
Why?
|
| Elasticity | 3 | 2009 | 652 | 0.090 |
Why?
|
| Thrombopoiesis | 1 | 2013 | 160 | 0.090 |
Why?
|
| Clofazimine | 1 | 1991 | 39 | 0.090 |
Why?
|
| Hemoglobins | 5 | 2013 | 1531 | 0.090 |
Why?
|
| Sex Factors | 3 | 2016 | 10611 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 1 | 1995 | 1077 | 0.090 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 26282 | 0.090 |
Why?
|
| Inositol | 1 | 2011 | 215 | 0.090 |
Why?
|
| Leukopenia | 1 | 2011 | 213 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2017 | 1475 | 0.090 |
Why?
|
| Extracellular Matrix | 3 | 2003 | 1727 | 0.090 |
Why?
|
| Drug Users | 1 | 2012 | 133 | 0.090 |
Why?
|
| Software | 1 | 2024 | 4462 | 0.090 |
Why?
|
| Antigens, Neoplasm | 3 | 2006 | 1995 | 0.090 |
Why?
|
| Macromolecular Substances | 2 | 2005 | 1430 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 1475 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2014 | 619 | 0.080 |
Why?
|
| Multivariate Analysis | 7 | 2016 | 12059 | 0.080 |
Why?
|
| Lipase | 1 | 2012 | 320 | 0.080 |
Why?
|
| Injections, Subcutaneous | 3 | 2018 | 682 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2021 | 637 | 0.080 |
Why?
|
| Choline | 1 | 2011 | 511 | 0.080 |
Why?
|
| Biophysical Phenomena | 3 | 2002 | 318 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2010 | 168 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2011 | 296 | 0.080 |
Why?
|
| Creatine | 1 | 2011 | 424 | 0.080 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2012 | 618 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1993 | 663 | 0.080 |
Why?
|
| Colon | 3 | 2005 | 1796 | 0.080 |
Why?
|
| Polytetrafluoroethylene | 1 | 2010 | 242 | 0.080 |
Why?
|
| Peptide Fragments | 5 | 2006 | 5126 | 0.080 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 622 | 0.080 |
Why?
|
| Biophysics | 3 | 2002 | 375 | 0.080 |
Why?
|
| Aspartic Acid | 1 | 2011 | 575 | 0.080 |
Why?
|
| Anemia, Hemolytic | 1 | 2010 | 164 | 0.080 |
Why?
|
| Killer Cells, Natural | 2 | 2011 | 2206 | 0.080 |
Why?
|
| Hepatitis C Antibodies | 1 | 2009 | 151 | 0.080 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2009 | 141 | 0.080 |
Why?
|
| Molecular Weight | 2 | 2005 | 2160 | 0.080 |
Why?
|
| Patient Admission | 1 | 2016 | 1365 | 0.080 |
Why?
|
| Uncertainty | 1 | 2013 | 763 | 0.080 |
Why?
|
| Head | 1 | 2014 | 926 | 0.080 |
Why?
|
| Algorithms | 4 | 2024 | 14064 | 0.070 |
Why?
|
| Cystatins | 1 | 2008 | 55 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 1997 | 2141 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2017 | 2248 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2017 | 1590 | 0.070 |
Why?
|
| Area Under Curve | 4 | 2015 | 1637 | 0.070 |
Why?
|
| Intestinal Absorption | 2 | 2004 | 400 | 0.070 |
Why?
|
| Pentanoic Acids | 1 | 2007 | 19 | 0.070 |
Why?
|
| Publishing | 1 | 2015 | 836 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 1930 | 0.070 |
Why?
|
| Patient Compliance | 3 | 2013 | 2693 | 0.070 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 770 | 0.070 |
Why?
|
| Mucus | 1 | 2009 | 346 | 0.070 |
Why?
|
| Splenic Artery | 1 | 2007 | 58 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 20690 | 0.070 |
Why?
|
| Fluorescent Dyes | 4 | 1999 | 1927 | 0.070 |
Why?
|
| Triglycerides | 1 | 2015 | 2440 | 0.070 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2008 | 97 | 0.070 |
Why?
|
| Phase Transition | 1 | 2007 | 69 | 0.070 |
Why?
|
| Intestinal Polyps | 1 | 1987 | 105 | 0.070 |
Why?
|
| Risk | 1 | 2019 | 9599 | 0.070 |
Why?
|
| Acute Disease | 3 | 2006 | 7236 | 0.070 |
Why?
|
| Dietary Supplements | 2 | 2011 | 3427 | 0.070 |
Why?
|
| Cysts | 1 | 2012 | 684 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2012 | 11030 | 0.070 |
Why?
|
| Colonic Diseases, Functional | 1 | 1986 | 38 | 0.070 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 8037 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 682 | 0.070 |
Why?
|
| Treatment Failure | 4 | 2016 | 2653 | 0.070 |
Why?
|
| Risk Factors | 9 | 2022 | 74850 | 0.070 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2004 | 694 | 0.070 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 536 | 0.070 |
Why?
|
| Renal Circulation | 1 | 2007 | 288 | 0.070 |
Why?
|
| Diffusion | 2 | 1999 | 808 | 0.070 |
Why?
|
| Cystatin C | 1 | 2008 | 272 | 0.070 |
Why?
|
| Hepatic Artery | 1 | 2007 | 233 | 0.070 |
Why?
|
| Sodium | 1 | 2011 | 1591 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 3 | 2009 | 2627 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2007 | 705 | 0.060 |
Why?
|
| Ubiquitin | 1 | 2011 | 839 | 0.060 |
Why?
|
| Peptides | 3 | 1999 | 4331 | 0.060 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 505 | 0.060 |
Why?
|
| Serologic Tests | 1 | 2008 | 382 | 0.060 |
Why?
|
| Thrombopoietin | 1 | 2008 | 225 | 0.060 |
Why?
|
| Helicobacter pylori | 1 | 2009 | 380 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2270 | 0.060 |
Why?
|
| Prednisone | 2 | 2008 | 1566 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2010 | 736 | 0.060 |
Why?
|
| Vascular Resistance | 2 | 2007 | 939 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7842 | 0.060 |
Why?
|
| Phlebitis | 1 | 2005 | 34 | 0.060 |
Why?
|
| Carbohydrate Metabolism | 1 | 1986 | 261 | 0.060 |
Why?
|
| Sciuridae | 2 | 1997 | 79 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8522 | 0.060 |
Why?
|
| Fibrinolysis | 2 | 2001 | 331 | 0.060 |
Why?
|
| Microscopy, Atomic Force | 1 | 2005 | 250 | 0.060 |
Why?
|
| Transaminases | 1 | 2005 | 199 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2024 | 3801 | 0.060 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 916 | 0.060 |
Why?
|
| Protein Conformation | 2 | 2005 | 3945 | 0.060 |
Why?
|
| Insulin Resistance | 2 | 2010 | 3988 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1993 | 1724 | 0.060 |
Why?
|
| MicroRNAs | 2 | 2011 | 3788 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2011 | 1314 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 1998 | 1800 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 2 | 2005 | 580 | 0.060 |
Why?
|
| Ileal Neoplasms | 1 | 1984 | 20 | 0.060 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2004 | 28 | 0.060 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2006 | 527 | 0.060 |
Why?
|
| Molecular Conformation | 1 | 2005 | 539 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 12973 | 0.060 |
Why?
|
| Cardiac Output | 1 | 2007 | 838 | 0.060 |
Why?
|
| Antioxidants | 1 | 2012 | 1671 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2012 | 4641 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3816 | 0.060 |
Why?
|
| Blood Coagulation Disorders | 1 | 2007 | 351 | 0.060 |
Why?
|
| RNA, Messenger | 5 | 2006 | 12768 | 0.060 |
Why?
|
| Integrin alpha1beta1 | 1 | 2003 | 8 | 0.060 |
Why?
|
| Integrin alpha2beta1 | 1 | 2003 | 17 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2021 | 254 | 0.060 |
Why?
|
| Protective Agents | 1 | 2005 | 151 | 0.060 |
Why?
|
| Growth Substances | 2 | 2003 | 758 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2010 | 889 | 0.060 |
Why?
|
| Iron Overload | 1 | 2006 | 245 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 663 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 2307 | 0.050 |
Why?
|
| Drug Implants | 1 | 2004 | 230 | 0.050 |
Why?
|
| Interferon-beta | 1 | 2006 | 346 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2014 | 8724 | 0.050 |
Why?
|
| Anilino Naphthalenesulfonates | 2 | 1995 | 16 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 1121 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 1463 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2018 | 4424 | 0.050 |
Why?
|
| Blotting, Western | 4 | 2006 | 5019 | 0.050 |
Why?
|
| Clostridium | 1 | 2023 | 100 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2011 | 3678 | 0.050 |
Why?
|
| Microscopy, Electron | 2 | 1997 | 2543 | 0.050 |
Why?
|
| Bradycardia | 1 | 1985 | 304 | 0.050 |
Why?
|
| Mucin-1 | 2 | 2006 | 535 | 0.050 |
Why?
|
| Gels | 2 | 2007 | 420 | 0.050 |
Why?
|
| Viral Core Proteins | 2 | 2012 | 158 | 0.050 |
Why?
|
| Mental Disorders | 2 | 2017 | 6870 | 0.050 |
Why?
|
| Membrane Proteins | 4 | 2012 | 7847 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2015 | 5987 | 0.050 |
Why?
|
| Macrophages | 1 | 2017 | 5772 | 0.050 |
Why?
|
| Fluoresceins | 2 | 2009 | 234 | 0.050 |
Why?
|
| Alkaline Phosphatase | 2 | 2019 | 855 | 0.050 |
Why?
|
| Body Weight | 2 | 2010 | 4627 | 0.050 |
Why?
|
| Glycosylation | 1 | 2005 | 1099 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 2395 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 1673 | 0.050 |
Why?
|
| Sphingomyelins | 1 | 2002 | 102 | 0.050 |
Why?
|
| Matrix Metalloproteinases | 2 | 2003 | 392 | 0.050 |
Why?
|
| Light | 2 | 1999 | 1364 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 2227 | 0.050 |
Why?
|
| Cytokines | 4 | 2007 | 7417 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2014 | 3078 | 0.050 |
Why?
|
| Amino Acid Sequence | 9 | 1999 | 13398 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 1607 | 0.050 |
Why?
|
| Logistic Models | 4 | 2013 | 13273 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2005 | 673 | 0.050 |
Why?
|
| Antigens, CD1 | 1 | 2004 | 434 | 0.050 |
Why?
|
| Energy Intake | 1 | 1989 | 2141 | 0.050 |
Why?
|
| Abdominal Pain | 2 | 2005 | 1069 | 0.050 |
Why?
|
| Health Surveys | 1 | 2011 | 4058 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2010 | 18074 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 1769 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2017 | 6274 | 0.050 |
Why?
|
| Actins | 2 | 2019 | 2057 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5691 | 0.050 |
Why?
|
| Analgesics | 1 | 2008 | 1057 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 11508 | 0.050 |
Why?
|
| Georgia (Republic) | 1 | 2020 | 39 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 11196 | 0.040 |
Why?
|
| Lipoproteins | 2 | 2021 | 870 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2005 | 630 | 0.040 |
Why?
|
| Collagen Type IV | 1 | 2001 | 124 | 0.040 |
Why?
|
| Estradiol | 2 | 2005 | 1947 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 993 | 0.040 |
Why?
|
| HIV | 1 | 2007 | 1587 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 2010 | 4617 | 0.040 |
Why?
|
| Gene Expression | 3 | 2012 | 7581 | 0.040 |
Why?
|
| Intestinal Obstruction | 1 | 1984 | 433 | 0.040 |
Why?
|
| Georgia | 1 | 2020 | 186 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2012 | 4405 | 0.040 |
Why?
|
| Inflammation | 2 | 2012 | 10843 | 0.040 |
Why?
|
| Apolipoproteins B | 1 | 2021 | 385 | 0.040 |
Why?
|
| North America | 2 | 2018 | 1287 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2012 | 9656 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2004 | 1751 | 0.040 |
Why?
|
| Osmolar Concentration | 2 | 2007 | 655 | 0.040 |
Why?
|
| Rats | 3 | 2008 | 23708 | 0.040 |
Why?
|
| Protein Binding | 3 | 2005 | 9296 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2010 | 18292 | 0.040 |
Why?
|
| Venous Pressure | 1 | 2019 | 55 | 0.040 |
Why?
|
| Patient Selection | 2 | 2018 | 4248 | 0.040 |
Why?
|
| Laminin | 1 | 2001 | 404 | 0.040 |
Why?
|
| Alanine | 1 | 2022 | 613 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2024 | 1186 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 3111 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2012 | 2787 | 0.040 |
Why?
|
| Phospholipids | 1 | 2002 | 776 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 7116 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2015 | 13042 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2005 | 856 | 0.040 |
Why?
|
| Static Electricity | 1 | 1999 | 258 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 1028 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 4055 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 2744 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 1987 | 1183 | 0.040 |
Why?
|
| Nutrition Surveys | 2 | 2016 | 1735 | 0.040 |
Why?
|
| Rats, Inbred Lew | 1 | 1999 | 1167 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2022 | 893 | 0.040 |
Why?
|
| Heart Failure | 1 | 2022 | 11837 | 0.040 |
Why?
|
| Bethanechol | 1 | 1997 | 12 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2019 | 216 | 0.040 |
Why?
|
| Polystyrenes | 1 | 1997 | 102 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2008 | 2464 | 0.040 |
Why?
|
| Acrylic Resins | 1 | 1997 | 131 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2012 | 10086 | 0.030 |
Why?
|
| Rheology | 2 | 2009 | 347 | 0.030 |
Why?
|
| Muscle Tonus | 1 | 1997 | 82 | 0.030 |
Why?
|
| Lipoprotein(a) | 1 | 2021 | 488 | 0.030 |
Why?
|
| Sigmoidoscopes | 1 | 1996 | 5 | 0.030 |
Why?
|
| Albumins | 1 | 1999 | 578 | 0.030 |
Why?
|
| Cholecystokinin | 1 | 1997 | 114 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 8107 | 0.030 |
Why?
|
| Pronase | 1 | 1996 | 27 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1990 | 1527 | 0.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1997 | 261 | 0.030 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1985 | 982 | 0.030 |
Why?
|
| Molecular Sequence Data | 8 | 1999 | 17596 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2001 | 833 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1998 | 1346 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 1899 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 2838 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2004 | 1812 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2006 | 3684 | 0.030 |
Why?
|
| Interleukin-10 | 3 | 2012 | 1181 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2004 | 1804 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 1996 | 150 | 0.030 |
Why?
|
| Exanthema | 2 | 2011 | 503 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 2242 | 0.030 |
Why?
|
| Egypt | 2 | 2007 | 100 | 0.030 |
Why?
|
| Chemical Precipitation | 1 | 1995 | 173 | 0.030 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 1995 | 91 | 0.030 |
Why?
|
| Lipids | 2 | 2004 | 3317 | 0.030 |
Why?
|
| Endometriosis | 1 | 1984 | 869 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1999 | 1885 | 0.030 |
Why?
|
| Energy Transfer | 1 | 1995 | 108 | 0.030 |
Why?
|
| Exercise | 1 | 2012 | 5936 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 2204 | 0.030 |
Why?
|
| Genes, Viral | 1 | 2016 | 654 | 0.030 |
Why?
|
| Proteins | 1 | 1990 | 5994 | 0.030 |
Why?
|
| Receptors, Lipoprotein | 1 | 1995 | 88 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1998 | 1159 | 0.030 |
Why?
|
| Species Specificity | 1 | 1999 | 2406 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1987 | 2530 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 5364 | 0.030 |
Why?
|
| Physicians | 1 | 2013 | 4591 | 0.030 |
Why?
|
| Lipid Metabolism | 2 | 2004 | 1893 | 0.030 |
Why?
|
| Estrogen Antagonists | 2 | 2005 | 151 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 1996 | 290 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2016 | 4130 | 0.030 |
Why?
|
| Phlebotomy | 1 | 2015 | 138 | 0.030 |
Why?
|
| Immunochemistry | 1 | 1994 | 116 | 0.030 |
Why?
|
| Remission Induction | 2 | 1991 | 2413 | 0.030 |
Why?
|
| Chromatography, Gel | 2 | 1996 | 631 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1995 | 1140 | 0.030 |
Why?
|
| Cysteine | 2 | 1997 | 897 | 0.030 |
Why?
|
| Linear Models | 2 | 2016 | 5873 | 0.030 |
Why?
|
| Decision Trees | 1 | 2016 | 509 | 0.030 |
Why?
|
| Cognition | 1 | 2011 | 7043 | 0.030 |
Why?
|
| Depression | 1 | 2013 | 8223 | 0.030 |
Why?
|
| Spleen | 1 | 1999 | 2294 | 0.030 |
Why?
|
| Crystallography | 1 | 1993 | 110 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2010 | 637 | 0.030 |
Why?
|
| Particle Size | 1 | 1997 | 1630 | 0.030 |
Why?
|
| CpG Islands | 1 | 2018 | 1207 | 0.030 |
Why?
|
| Probability | 1 | 2018 | 2474 | 0.030 |
Why?
|
| Mice | 8 | 2010 | 81782 | 0.030 |
Why?
|
| Headache | 2 | 2013 | 1261 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 147 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2007 | 8530 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 4037 | 0.020 |
Why?
|
| Hypertension | 1 | 2012 | 8616 | 0.020 |
Why?
|
| Portal System | 1 | 1992 | 49 | 0.020 |
Why?
|
| Metaplasia | 1 | 1993 | 325 | 0.020 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Receptors, KIR2DL3 | 1 | 2011 | 15 | 0.020 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2011 | 27 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2013 | 380 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2011 | 37 | 0.020 |
Why?
|
| Catheterization | 1 | 1996 | 1426 | 0.020 |
Why?
|
| Apoptosis | 1 | 2007 | 9505 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1999 | 2390 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 1996 | 557 | 0.020 |
Why?
|
| Water | 1 | 1997 | 1416 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 12529 | 0.020 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2011 | 113 | 0.020 |
Why?
|
| Plasma | 1 | 2014 | 583 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 2194 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 4563 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 1993 | 788 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 2006 | 3212 | 0.020 |
Why?
|
| Prothrombin | 1 | 2011 | 193 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1996 | 1666 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 1970 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1990 | 212 | 0.020 |
Why?
|
| Half-Life | 1 | 2011 | 645 | 0.020 |
Why?
|
| Binding Sites | 1 | 1999 | 5999 | 0.020 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1990 | 123 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1990 | 289 | 0.020 |
Why?
|
| Gastric Juice | 1 | 1989 | 59 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2015 | 458 | 0.020 |
Why?
|
| Viral Envelope Proteins | 1 | 1993 | 639 | 0.020 |
Why?
|
| Trypsin | 1 | 1990 | 487 | 0.020 |
Why?
|
| Nausea | 1 | 2013 | 678 | 0.020 |
Why?
|
| Obesity | 1 | 2012 | 13082 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2010 | 23597 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3430 | 0.020 |
Why?
|
| Urease | 1 | 2009 | 43 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 2970 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1991 | 642 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 2 | 1987 | 139 | 0.020 |
Why?
|
| Research Design | 2 | 2018 | 6204 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2012 | 616 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1995 | 1415 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2010 | 738 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1995 | 1362 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2010 | 12129 | 0.020 |
Why?
|
| Viremia | 1 | 2012 | 727 | 0.020 |
Why?
|
| Virus Replication | 1 | 2017 | 2450 | 0.020 |
Why?
|
| Models, Molecular | 1 | 1999 | 5377 | 0.020 |
Why?
|
| Fasting | 1 | 2015 | 1606 | 0.020 |
Why?
|
| Peptic Ulcer Perforation | 1 | 1988 | 23 | 0.020 |
Why?
|
| Placebos | 1 | 2013 | 1659 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 598 | 0.020 |
Why?
|
| Duodenal Ulcer | 1 | 1988 | 117 | 0.020 |
Why?
|
| Jaundice, Obstructive | 1 | 2008 | 22 | 0.020 |
Why?
|
| Genome-Wide Association Study | 2 | 2021 | 12803 | 0.020 |
Why?
|
| Immunoassay | 1 | 2011 | 742 | 0.020 |
Why?
|
| Hepatitis B Antibodies | 1 | 1988 | 156 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2018 | 22228 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 1990 | 608 | 0.020 |
Why?
|
| Mucin-5B | 2 | 1998 | 148 | 0.020 |
Why?
|
| Epitopes | 1 | 1993 | 2523 | 0.020 |
Why?
|
| Urea | 1 | 2009 | 449 | 0.020 |
Why?
|
| Safety Management | 1 | 2012 | 764 | 0.020 |
Why?
|
| California | 1 | 2011 | 1435 | 0.020 |
Why?
|
| Gallbladder Emptying | 1 | 2006 | 14 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2011 | 1133 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 1132 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 1470 | 0.020 |
Why?
|
| Base Sequence | 4 | 1999 | 12405 | 0.020 |
Why?
|
| Lactulose | 1 | 1986 | 30 | 0.020 |
Why?
|
| Perception | 1 | 2013 | 1204 | 0.020 |
Why?
|
| Glycolysis | 1 | 1990 | 837 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2007 | 197 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1433 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2021 | 6612 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2015 | 1142 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1996 | 0.020 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2005 | 58 | 0.020 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2005 | 58 | 0.020 |
Why?
|
| Hydrogen | 1 | 1986 | 168 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 6838 | 0.020 |
Why?
|
| Outpatients | 1 | 2013 | 1595 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 1729 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6503 | 0.020 |
Why?
|
| Eating | 1 | 1992 | 1539 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 1996 | 5300 | 0.020 |
Why?
|
| Breath Tests | 1 | 1986 | 297 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 12235 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2018 | 6251 | 0.010 |
Why?
|
| Cell Movement | 3 | 2003 | 5190 | 0.010 |
Why?
|
| DNA, Complementary | 2 | 1998 | 1984 | 0.010 |
Why?
|
| Castration | 1 | 2004 | 149 | 0.010 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2004 | 31 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2004 | 85 | 0.010 |
Why?
|
| Riboflavin Deficiency | 1 | 1983 | 3 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3661 | 0.010 |
Why?
|
| Vitamin B 6 Deficiency | 1 | 1983 | 18 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1987 | 1695 | 0.010 |
Why?
|
| Ascorbic Acid Deficiency | 1 | 1983 | 26 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 1850 | 0.010 |
Why?
|
| Data Collection | 1 | 2013 | 3318 | 0.010 |
Why?
|
| Antigens, CD1d | 1 | 2004 | 226 | 0.010 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 9541 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2005 | 612 | 0.010 |
Why?
|
| Estrogen Receptor beta | 1 | 2004 | 171 | 0.010 |
Why?
|
| Thiamine Deficiency | 1 | 1983 | 48 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 2925 | 0.010 |
Why?
|
| Gastrointestinal Transit | 1 | 2004 | 102 | 0.010 |
Why?
|
| 1,2-Dipalmitoylphosphatidylcholine | 1 | 2002 | 40 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2016 | 3615 | 0.010 |
Why?
|
| Cell Line | 3 | 2004 | 15540 | 0.010 |
Why?
|
| Enterocytes | 1 | 2004 | 220 | 0.010 |
Why?
|
| Disease Management | 1 | 2013 | 2530 | 0.010 |
Why?
|
| Integrin alpha Chains | 1 | 2003 | 93 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2012 | 6321 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2006 | 573 | 0.010 |
Why?
|
| Clone Cells | 2 | 1998 | 1670 | 0.010 |
Why?
|
| Incidence | 2 | 2013 | 21513 | 0.010 |
Why?
|
| Rectum | 1 | 1987 | 895 | 0.010 |
Why?
|
| Chemotactic Factors | 1 | 2003 | 195 | 0.010 |
Why?
|
| Gastrointestinal Motility | 1 | 2004 | 235 | 0.010 |
Why?
|
| Hydrogen Bonding | 1 | 2002 | 290 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2004 | 388 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1997 | 2743 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2004 | 517 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 14745 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2006 | 701 | 0.010 |
Why?
|
| Ileum | 1 | 1984 | 558 | 0.010 |
Why?
|
| Comorbidity | 1 | 2016 | 10575 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2012 | 5880 | 0.010 |
Why?
|
| Prisoners | 1 | 2005 | 315 | 0.010 |
Why?
|
| Bile Acids and Salts | 1 | 2004 | 398 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1992 | 4186 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2004 | 592 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1997 | 4163 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1989 | 1620 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2004 | 566 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2003 | 614 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2004 | 1616 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 697 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1986 | 1216 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 5889 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2004 | 1040 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2004 | 1074 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2004 | 1250 | 0.010 |
Why?
|
| TATA Box | 1 | 1998 | 127 | 0.010 |
Why?
|
| Mice, Knockout | 2 | 2004 | 14450 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2006 | 2141 | 0.010 |
Why?
|
| Viral Structural Proteins | 1 | 1998 | 93 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 6202 | 0.010 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 1786 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1985 | 958 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 2120 | 0.010 |
Why?
|
| Chymotrypsin | 1 | 1997 | 136 | 0.010 |
Why?
|
| Feces | 1 | 2004 | 1503 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2004 | 1247 | 0.010 |
Why?
|
| Genomic Library | 1 | 1997 | 189 | 0.010 |
Why?
|
| Alcoholism | 1 | 1988 | 1978 | 0.010 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 1996 | 44 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1997 | 259 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 6058 | 0.010 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 1996 | 18 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1997 | 363 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1997 | 848 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 2004 | 1271 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2012 | 8060 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 5738 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 1996 | 6958 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 2462 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 11895 | 0.010 |
Why?
|
| Sepharose | 1 | 1996 | 100 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 3829 | 0.010 |
Why?
|
| Temperature | 1 | 2002 | 2226 | 0.010 |
Why?
|
| Scavenger Receptors, Class B | 1 | 1995 | 84 | 0.010 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1996 | 168 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 3599 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5509 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 1995 | 123 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1997 | 780 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1995 | 772 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1995 | 300 | 0.010 |
Why?
|
| Introns | 1 | 1997 | 965 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 2172 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 2824 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1998 | 825 | 0.010 |
Why?
|
| Rural Population | 1 | 2004 | 2318 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1997 | 658 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1998 | 1964 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1998 | 1716 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1996 | 520 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 3213 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1996 | 1142 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1997 | 681 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 1993 | 236 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 1998 | 18962 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 1995 | 699 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 890 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 30192 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1993 | 328 | 0.010 |
Why?
|
| Exons | 1 | 1997 | 2393 | 0.010 |
Why?
|
| Veterans | 1 | 2005 | 2667 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 36426 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 4909 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 12822 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10426 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2013 | 42510 | 0.010 |
Why?
|
| Pepstatins | 1 | 1989 | 10 | 0.010 |
Why?
|
| Sucralfate | 1 | 1989 | 12 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 1995 | 596 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1996 | 1588 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1998 | 1961 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1992 | 1479 | 0.000 |
Why?
|
| Peptic Ulcer | 1 | 1989 | 214 | 0.000 |
Why?
|
| HLA Antigens | 1 | 1993 | 1338 | 0.000 |
Why?
|
| Ireland | 1 | 1988 | 171 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 22327 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1986 | 7473 | 0.000 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 4780 | 0.000 |
Why?
|
| Tranexamic Acid | 1 | 1989 | 174 | 0.000 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 17060 | 0.000 |
Why?
|
| Diet | 1 | 2004 | 8087 | 0.000 |
Why?
|
| Child | 1 | 2013 | 80568 | 0.000 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1985 | 336 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1989 | 1433 | 0.000 |
Why?
|
| Pregnancy | 1 | 2004 | 30230 | 0.000 |
Why?
|
| Brain | 1 | 2002 | 27179 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1988 | 15802 | 0.000 |
Why?
|